(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide - 2'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 3The most effective method to Guarantee Thorough Inclusion in Senior Protection.
- 4Everyday Seasonal Positions That Compensate Fairly in the US
- 5Nutrient Rich Natural products: Lift Your Wellbeing
- Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- 4 Sound blocking Earphones for Prevalent Sound and Solace
- Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- New dietary guidelines recommend more dairy, meat and fats: What to know
- Vote In favor of Your Favored Kind Of Organic product
- When does Spotify Wrapped come out? The music streamer says 'soon.'
- Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- 6 Web-based Course Stages for Successful Learning and Educating
- Vote in favor of your #1 sort of juice
